Abstract: Current pharmacologic interventions in lipid metabolism are insufficient in a subset of patients at increased risk of cardiovascular disease. In particular, several monogenetic disorders of lipid metabolism with diverse clinical complications are beyond treatment to date. Somatic gene transfer is a potential approach to treat these disorders. This review describes the efforts made thus far to develop gene therapy for 3 major classes of dyslipidemia: Increased levels of lowdensity lipoprotein cholesterol, reduced levels of high-density lipoprotein cholesterol and increased plasma triglyceride levels. For many of the genetic causes underlying these conditions, proof-of-principle studies have been performed and in combination with improved vectors some of these strategies may be feasible for clinical use in the future.
INTRODUCTION
Disorders of lipoprotein metabolism are often implicated in pro-atherogenic processes which can ultimately result in cardiovascular disease. Increased levels of low-density lipoprotein cholesterol (LDL-C), reduced levels of highdensity lipoprotein cholesterol (HDL-C) and increased plasma triglyceride (TG) levels are recognized as independent risk factors for cardiovascular morbidity and mortality. Pharmacologic interventions with statins (lowering plasma LDL-C levels), fibrates and bile sequestrants (lowering plasma TG) and niacin (increasing HDL-C levels) have been shown to confer significant favorable changes in terms of the cardiovascular risk profile. These drug classes are generally effective when the respective metabolic pathways are largely intact. In monogenetic disorders that result in complete deficiency of critical proteins in such pathways, however, these drugs are in broad terms ineffective. Homozygosity for loss of function mutations in key proteins of LDL, HDL or TG metabolism have been shown to underlie various dramatic phenotypes for which no treatment is available. In such cases, somatic gene transfer aimed at introducing the expression of wildtype proteins could theoretically offer a therapeutic solution.
This review summarizes the efforts made in developing gene therapy to correct dyslipidemias thereby focusing on familial hypercholesterolemia (elevated LDL-C levels), hypoalphalipoproteinemia (low levels of HDL-C) and hypertriglyceridemia. We have discussed all published efforts in this specific research field and provide brief information on more recent advances in gene delivery that may become available for the treatment of dyslipidemia in the future. For a more general review on gene therapy for specific lipid disorders, we wish to refer to a recent review by Broedl and Rader [Broedl et al., 2005] . 
LOW-DENSITY LIPOPROTEINS

Genetic Causes of Elevated Low-Density LipoproteinCholesterol
Two well-defined hereditary disorders cause elevations of LDL-C levels with consequent premature atherosclerosis and cardiovascular death. The best-known of these is familial hypercholesterolemia (FH; frequency 1:400 amongst Caucasians, [Goldstein et al., 2001] ) which is caused by LDL receptor deficiency. Familial defective apolipoprotein B-100 (FDB) constitutes the second but less frequent disorder, caused by loss of apoB100 function, a protein that is part of the LDL particle and serves as the ligand for the LDL receptor. Familial combined hyperlipidemia (FCH) constitutes a third disorder which, in addition to hypercholesterolemia, is also characterized by hypertriglyceridemia. However, the latter polygenetic disorder is not well-defined to date and lifestyle characteristics are known to play an important role in expression of the phenotype.
Statins are effective LDL-C lowering drugs that can reduce cardiovascular disease risk by 35%, however, these drugs can produce suboptimal effects, particularly in patients with homozygous FH [Naoumova et al., 2004] . Current treatment for homozygous FH patients therefore consists of repeated LDL apheresis or ectopic liver transplantation. For these cases, gene transfer strategies to induce LDL receptor expression or reduce apoB expression may bring relief especially since these individuals present with pronounced atherosclerosis and premature death. Gene therapies aimed at lowering LDL-C have focused on correcting homozygous FH, the obvious target group. If successful, these strategies might eventually also bring relief to other patients such as those suffering from heterozygous FH who don't respond well to statin therapy.
In the sections below we have discriminated between means directed at increasing LDL removal from the circulation and those that are aimed at reducing hepatic LDL production (see Fig. 1 ). Fig. (1) . Schematic representation of proposed gene therapeutic strategies to correct LDL receptor deficiency, i.e. familial hypercholesterolemia. A) Normal situation and B) LDL receptor deficient situation. Proposed gene therapeutic strategies for correction: C) Over expression of the LDL receptor increases uptake of LDL, D) Over expression of the VLDL receptor increases uptake of LDL-precursor IDL, E) Reducing apo B100 secretion by inducing apo Bediting. Consequently less LDL is formed, instead apoB48-containing particles are formed which are probably removed by the liver via the LRP receptor, F) Inducing apo B mRNA degradation resulting in less LDL particles and G) Increasing hepatic cholesterol removal by over expression of Cyp7alpha-hydroxylase results in less LDL. In red deficiencies and in green gene therapeutic corrections and consequent effects.
INCREASING LDL REMOVAL FROM THE CIRCULATION
Over-Expression of the LDL Receptor
Non-Viral Strategies
Viral vectors have been shown effective in introducing foreign genes into host cells; however, with this strategy one also introduces viral capsid proteins that are able to evoke a host immune response in addition to the risk of viral replication and insertional mutagenesis. To circumvent this, nonviral vectors for DNA delivery to correct FH have been investigated since the beginning of gene therapeutic efforts. The general strategy is to complex DNA encoding the transgene to molecules with a high affinity for the target cells. Despite the above-mentioned advantages over viral vectors, non-viral strategies have their own particular drawbacks. Most important among these are the toxicity of the cationic complexing molecules, low transduction capacity and relatively short transgene expression due to lysosomal breakdown. For these reasons, only three , relative unsuccessful attempts to treat FH in this way have been described to date: In 1992, Wilson et al., described complexing the LDL receptor DNA with poly-L-lysine to asialoorosomucoid, a protein that has high affinity for the hepatic asialoglycoprotein receptor [Wilson et al., 1992] . Infusing such complexes into the ear vein of LDL receptor deficient rabbits, led to a 10 day liver-specific expression of the LDL receptor which in turn led to a 2 to 4% reconstitution of wild-type LDL receptor levels, yet causing a marked 20-30% decrease in plasma cholesterol levels. Other investigators used cationic liposome-DNA complexes attached to transferrin as the ligand [Shichiri et al., 2003 ]. An intriguing feature of this approach was that gene transfer was directed at circulating leukocytes instead of hepatocytes thereby transforming the leukocyte pool into a sink for cholesterol, which induced plasma cholesterol-lowering. However, correction was again incomplete and transient (21 days) probably due to limited lifetime of circulating leukocytes. Razzini et al., used a hydrodynamicsbased gene transfer approach to express a transferrin-LDL receptor fusion protein in the liver [Razzini et al., 2004] . With this method, a rapid infusion of a relatively large volume of plasmid DNA produces a hydrodynamic pressure that is associated with an increased uptake of plasmid DNA by hepatocytes. This approach resulted in expression of the fusion protein peaking at 18 to 24 hours post-injection and subsequent disappearance of expression after 120 hours. Using LDL receptor deficient mice, the secreted fusion protein was capable of binding LDL and mediating uptake of the complex by the liver. Consequently, the clearance rate of infused labelled LDL was normalized. Despite, the drawbacks of low transduction efficacy and short-lived expression observed in this study, more advanced hydrodynamic approaches might, however, prove useful for some applications as recently reviewed by Miao et al., [Miao 2005 ].
To date, the problems of transient and low transgene expression using non-viral vectors have still not been overcome but non-viral vectors enjoy renewed attention due to the persisting problems with immune responses when using viral vectors. Improvements to increase the potential use of nonviral vectors are therefore still ongoing and include among others reducing toxicity by structural modifications of the DNA complexing molecules [Lv et al., 2006] , improving transfection efficiency by increasing the vector circulation time [Awasthi et al., 2003] , improving tissue-specific targeting using virosomes [Felnerova et al., 2004; Daemen et al., 2005] and increasing persistence of expression using sitespecific integration methods such as transposons [Izsvak et al., 2004] and integrases [Groth et al., 2000] .
Cell-Based Gene Therapy Using Retrovirus
Several investigators have attempted to correct FH by using cell-based ex vivo gene therapy, i.e. transplanting in vitro genotype-corrected cells into a deficient host. The first steps into this direction were already taken in 1986 when Kingsley et al., demonstrated that transfection of LDL receptor-deficient Chinese hamster ovary (CHO) cells in vitro with human DNA led to expression of the LDL receptor and corrected the multiple glycosylation defects of these cells [Kingsley et al., 1986] . Subsequently, retroviral vectors introducing the LDL receptor gene were shown to transduce primary hepatocytes and fibroblasts isolated from the Watanabe heritable hyperlipidemic (WHHL) rabbit, a naturallyoccurring animal model for FH [Wilson et al., 1988; Miyanohara et al., 1988] . After introduction of the LDL receptor, these primary cells were able to take up and degrade LDL. In addition, this physiological correction resulted in decreased intracellular cholesterol synthesis, an important mechanism in controlling intracellular cholesterol levels [Dichek et al., 1991] . In 1990, Wilson et al., took the next step and harvested hepatocytes from WHHL rabbits, cultured and infected them with recombinant retroviruses expressing the human LDL receptor gene and subsequently infused these cells into the portal veins of other WHHL recipients [Wilson et al., 1990] . All 7 recipients demonstrated significant decreases in serum cholesterol on days 2-6 following infusion, whereas animals treated with mock-infected hepatocytes showed no effect. However, from day 3 onwards, serum cholesterol levels slowly started to increase again reaching pretreatment levels at day 6-8, most likely because of loss of the transplanted allogenic cells due to rejection. This thought was strengthened by data showing prolonged expression when using autologous fibroblasts [Dichek et al., 1991] or hepatocytes [Chowdhury et al., 1991] . Specifically, Chowdhury et al., used autologous hepatocytes and moreover transferred the rabbit LDL receptor instead of the human LDL receptor. This rendered stable presence of recombinant LDL receptor RNA in both liver and spleen for up to 6.5 months [Chowdhury et al., 1991] . Although only a 2 to 4% reconstitution of normal LDL receptor hepatic mRNA levels was achieved, this led to a striking 30% reduction of serum cholesterol levels. In combination with the lack of antibodies to the transfected rabbit LDL receptor [Chowdhury et al., 1991] , these data paved the road for a first gene therapy trial to correct FH in humans. Employing essentially the same technique a total of 5 FH patients were treated [Grossman et al., 1994; Grossman et al., 1995] . Although the invasive procedures of partial hepatectomy and reinfusion of cells was tolerated quite well, serum cholesterol reductions were modest and metabolic responses after gene transfer varied considerably among the 5 recipients. As the authors stated: 'Data from these 5 patients preclude a broader application of liver-directed gene therapy without modifications that consistently effect substantially greater gene transfer' [Grossman et al., 1995] . Although further efforts have been made to increase in vitro transduction efficiency [Pages et al., 1995] , the invasive procedures combined with the development of new methodologies and viral vectors capable of efficient in vivo infection have excluded this method from clinical use to date.
One cell-based strategy, employing pluripotent stem cells or progenitor cells, still has perspective because these are non-immunogenic cells and thus can be allogenically transplanted.
Only one such approach using human amniotic epithelial cells (HAECs) has currently been described as approach to increase LDL receptor expression. These investigators transduced HAECs in vitro with adenovirus expressing the LDL receptor and infused the manipulated cells into the ear vein of WHHL rabbits [Takahashi et al., 2001] . Although a decrease in cholesterol levels was noted in all 3 treated animals which persisted for at least 20 days in one animal, most HAECs were shown to become part of the endothelial lining of the hepatic vessels and only a few engrafted within the host hepatic tissue. Nevertheless, the use of such nonimmunogenic cells might offer possibilities for cell-based applications in the future and in particular human embryonic stem cells that still have the capacity to differentiate into various lineages [Menendez et al., 2005] .
First Systemic Application of Viral Vectors: FirstGeneration Adenoviral Vectors
The first studies into systemic gene delivery of the LDL receptor took advantage of the endogenous property of adenovirus to transduce hepatocytes with high efficiency in vivo. In mice, infusion of a first-generation adenovirus encoding the human LDL receptor induced within days high expression of the protein in predominantly hepatocytes [Ishibashi et al., 1993; Herz et al., 1993] and consequently normalization of the lipoprotein profile [Ishibashi et al., 1993] . However, these mice were sacrificed 4 days after virus injection, not permitting evaluation of persistence of gene expression. Using a similar approach but evaluating expression up to 20 days, an initial rapid drop in cholesterol levels was followed by a return to baseline levels within 2 weeks after administration of the virus Li et al., 1995] . Overall, the systemic use of adenovirus-mediated gene transfer appeared to produce only transient effects due to innate as well as adaptive immune responses (both cellular and humoral) against viral as well as transgenic proteins. Furthermore, it was shown that a second infusion of adenovirus failed to induce transgene expression due to formation of neutralizing antibodies upon first contact with adenovirus . The latter poses another challenge since a high percentage of the general human population suffers from adenoviral infections and is therefore likely to have neutralizing antibodies. Taken together, early experiments with adenovirus demonstrated that in vivo gene transfer can lead to a substantial therapeutic effect but with several important challenges to overcome. Interestingly, these experiments also demonstrated additional beneficial effects of expressing the LDL receptor, such as a concomitant increase of HDL-C and apolipoprotein AI [Brown et al., 1996] . However, they also posed a warning: induction of supra-physiological levels of the LDL receptor led to massive, toxic cholesterol accumulation in hepatocytes supposedly due to the limited capacity of conversion of the sequestered cholesterol into bile acids [Heeren et al., 1999; Cichon et al., 2004] .
To overcome some of the difficulties in these proof of principle studies with early viral vectors in the lipid field, since at the time there were no better alternative viral vectors, Pakkanen employed partial hepatectomy and ganciclovir to stimulate hepatic proliferation allowing in vivo infection by retroviral vectors [Pakkanen et al., 1999] while Stein et al., used strong anti-CD154 immunosuppression to enable prolonged expression with adenovirus [Stein et al., 2000] . However, the development of better-equipped viral vectors as discussed in the next paragraph has dismissed further research and use of such drastic approaches.
Systemic Application of Viral Vectors: Helper-Dependent Adenoviral, Lentiviral and Adeno-Associated Viral Vectors
Several viral vectors have been shown to be capable of inducing expression of the LDL receptor for several years and even life-long after one injection: 1) Helper-dependent adenovirus (Hd-Ad) also known as gutless adenovirus, are adenoviral vectors that lack the DNA sequences that encode for viral proteins. Eliminating all viral coding sequences prevents leak-through-expression of viral proteins that can evoke an adaptive immune response. HdAd vectors thus offer decreased host immune responses to viral proteins, decreased cellular toxicity of viral proteins and increased capacity to accommodate larger expression cassettes (up to 36 kb of DNA) compared to first or secondgeneration adenoviral vectosr (in which the viral genes are only partly eliminated [Alba et al., 2005] . However, producing these viral particles is challenging since it necessitates the use of helper adenovirus carrying all the coding regions for the viral particle structure. Hd-Ad viral vectors encoding for the LDL receptor have been shown to provide a life-long lipid reduction up to 90% and, importantly, reduced atherosclerotic burden in LDL receptor deficient mice. Untreated mice on an atherogenic diet for 20 weeks showed a 50% atherosclerotic lesion coverage of their aortas, whereas animals treated with Hd-Ad-LDLr were essentially lesion-free [Nomura et al., 2004] . When using the highest dose, however, 2 out of 8 animals developed antibodies against the transgenic product with a consequential loss of therapeutic effect. However, in the lower-dose group, which also showed a pronounced 80% decrease in cholesterol levels, such antibody response did not develop.
2) Third-generation, self-inactivating lentiviral vectors with the use of liver-specific promoters. These vectors have also been reported to induce LDL receptor gene expression for at least 2 years in WHHL rabbits. These investigators reported a mean cholesterol decrease of 34% compared to animals treated with green fluorescent protein [Kankkonen et al., 2004] . Unfortunately, the effect of LDL receptor expression on atherosclerosis was not investigated. The vector was considered safe with regard to inflammation, hepatotoxicity and cancer. In contrast to Hd-Ad, lentiviral vectors do not require helper-virus and integrate stably into the genome of target cells, which can be both dividing and non-dividing cells. This integration property in combination with liverspecific promoters allows for sustained expression but also increases the risk of insertional mutagenesis.
3) Adeno-associated virus (AAV) is a third vector that allows for long-term expression. Initial efforts using AAV serotype 2 (AAV2) with the LDL receptor gene driven by the CMV promoter produced low expression levels and induced an antibody response against the transgene in LDL receptor deficient mice that caused loss of transgene expression within 4 weeks [Chen et al., 2000] . It has been suggested that the CMV promoter might either have acted as an adjuvant for antibody formation [Nomura et al., 2004] or allowed for expression in antigen-presenting cells [Lebherz et al., 2004] . Indeed, use of AAV with the LDL receptor gene under control of a liver-specific promoter induced transgenic expression for at least 140 days without encountering expression-terminating immune responses [Lebherz et al., 2004] . In addition, the use of novel AAV serotypes 7 and 8 [Gao et al., 2002] was shown to increase hepatic expression of the LDL receptor compared to AAV2, resulting in a nearly complete normalization of lipid levels and an atherosclerosis reduction of approximately 50%.
Finally, Wade-Martins et al., recently proposed the use of a bacterial artificial chromosome introduced into highcapacity herpes-simplex virus (HSV) [Wade-Martins et al., 2003] . They inserted the complete LDL receptor locus (LDL receptor gene with 45 kb of endogenous flanking sequences) into HSV, a virus which is capable of infecting a wide range of cells, at least in vitro. The inclusion of the complete gene locus allowed for physiological regulation of gene expression in vitro, e.g. sensitivity to intracellular cholesterol levels due to presence of sterol-responsive elements. Application of such a vector, if proven safe and efficacious, may be preferred above approaches using constitutive promoters.
Over-Expression of the VLDL Receptor
An alternative to enhancing the removal of LDL particles is to stimulate the removal of their precursor particles in the circulation, i.e. intermediate-density lipoprotein (IDL) and very-low density lipoprotein (VLDL). In an effort to gain more insight in the biology of the then recently discovered VLDL receptor, Kobayashi et al., used adenovirus to over express the VLDL receptor in the liver of LDL receptor deficient mice [Kobayashi et al., 1996] . In this model, they identified IDL as the preferred substrate for the VLDL receptor with apoE as the functional ligand for liver uptake. Overexpression of the VLDL receptor reduced levels of IDL and consequently LDL. These data supported the idea of exchanging the LDL receptor for the VLDL receptor in a gene therapy effort to treat FH (see Fig. 1D ). The rationale for this is quite strong since the VLDL receptor expression lasted longer compared to the human LDL receptor due to the fact that the VLDL receptor protein did not act as a neo antigen in LDL receptor deficient mice [Kozarsky et al., 1996b; Chen et al., 2000] . Using AAV2 [Chen et al., 2000] or HdAd [Oka et al., 2001; Nomura et al., 2004] for VLDL receptor gene delivery in LDL receptor deficient mice on a Western-type diet proved efficacious in decreasing IDL/LDL cholesterol levels and atherosclerosis. Importantly, increased expression of the VLDL receptor in combination with a lowfat diet regimen was even shown to induce regression of advanced atherosclerotic lesions. [MacDougall et al., 2006] . Of note, regression of atherosclerosis is of crucial importance for putative future treatment of FH patients with established disease.
DECREASING LDL PRODUCTION Decreasing Levels of apoB-100
Another way of reducing LDL-C levels is to reduce LDL synthesis and/or secretion by the liver. Initial attempts to reduce apoB100 production made use of a natural-occurring mechanism that controls the fate of apoB100 mRNA. The apoB gene encodes both apolipoproteins B100 and B48. In the liver, apoB100 is produced from the complete transcript, whereas in intestinal cells the apoB100 mRNA is edited by an apoB mRNA-editing protein. This enzyme converts apoB100 mRNA into apoB48 mRNA by changing the first base of the glutamine codon (CAA) at residue 2153 causing a translational stop codon (UAA). In humans, the respective editing occurs exclusively in the intestine whereas rodents also have substantial expression of apoB mRNA-editing protein in the liver. Theoretically, up-regulation of apoB100 mRNA editing in the liver would thus lead to decreased synthesis of LDL (see Fig. 1E ). Indeed, adenoviral overexpression of apobec-1, a cytidine deaminase and the catalytic component of the apoB mRNA-editing protein complex, leads to nearly complete disappearance of apoB100 and an increase of circulating apoB48 in both mice and rabbits [Teng et al., 1994; Greeve et al., 1996; Kozarsky et al., 1996a; Teng et al., 1997] . Furthermore, the synthesized and secreted VLDL particles were found to be smaller while LDL particles from the normal size range disappeared [Teng et al., 1994] . Of note, the effect on total cholesterol levels in plasma was generally modest, with greatest reductions seen in adenovirus-treated LDL receptor deficient mice: 18% and 29% total cholesterol reduction in females and males, respectively. To our knowledge, no long-term experiments that employ the above strategy have been described to date.
Recently, other methods have been developed that inhibit protein synthesis by degrading specific mRNA sequences. One such strategy employs ribozymes, small RNA molecules with specific RNA cleaving capacity. Adenoviral expression of an apoB-specific ribozyme has been shown to decrease full-length apoB mRNA concentration and consequently the production of full-length apoB protein in vitro [Wang et al., 1999] as well as in vivo [Enjoji et al., 2000 ] (see Fig. 1F ). Instead, a truncated variant of the protein was formed which was mainly degraded intracellular. Inhibiting apoA100 protein synthesis with this adenoviral methodology lasted 2 weeks and led to marked reduction of LDL-C but also triglyceride levels in transgenic mice expressing human apoB and lacking hepatic apoB editing (Apobec1-/-ERhB-/-mice). More recently, Zhong et al., reported an AAV approach to express this ribozyme [Zhong et al., 2004] . Using AAV2, ribozyme production was evident for at least 150 days but expression levels were low and did not affect cholesterol levels. The recent description of self-complementary (sc) AAVs, eliminating the need of second-strand synthesis which was shown to increase both early onset and level of expression [McCarty et al., 2003; Wang et al., 2003b] , prompted these authors to compare the expression levels of their original single-stranded vector with a sc-vector in HEPG2 cells. Compared to the original vector, the sc-vector was 3-fold more effective with regard to expression of the ribozymes. At day 3 this resulted in a 47% reduction of apoB100 mRNA levels while the single-stranded vector did not affect apoB100 mRNA levels.
Short-hairpin (sh) RNAs have also been employed to specifically knock down apoB production. In this context, self-inactivating lentivirus used for stably transfecting HEPG2 cells with apoB-specific shRNA, was shown to reduce both cellular and secreted apoB by a marked 85% with persistence of this phenotype after 10 cell passages [Liao et al., 2006] .
Finally, a non-viral strategy using antisense oligonucleotides has recently been described which was shown to be very effective in reducing apoB100, but not apoB48, mRNA levels in mice [Crooke et al., 2005] . Specific 20-mer oligonucleotides were administered intraperitoneally, twice weekly for 6 weeks to C57/Bl6 wild-type mice, LDL receptor deficient mice and apoE deficient mice. Hepatic as well as intestinal apoB100 mRNA levels were reduced between 73% and 87% in all tested mouse models. These reductions were associated with a 25-55% decrease of plasma cholesterol, mainly caused by reductions in LDL-C levels but also in HDL-C. The apoE deficient mouse, however, only showed a decrease in the LDL-C fraction. Strikingly, 6 weeks after treatment was stopped, plasma cholesterol levels were still 38% decreased compared to pre-treatment levels (only tested in the high-fat fed C57/Bl6 mice). A good safety profile in combination with the effectiveness in reducing LDL-C allowed this strategy to be tested in patients. Results of the first trial with this specific oligonucleotide, ISIS 301012, have recently been published . This study demonstrates a maximum reduction of apoB of 50% in the 2 highest dose treatment groups, i.e. 200 and 400 mg ISIS 301012. Coincided with this apoB decrease was a maximum 35% reduction in LDL-C, remaining decreased up to 3 months after the last dose. Given the efficacy of this compound, a phase II study has now been completed and results are anticipated.
Increasing Cholesterol 7 -Hydroxylase
The conversion of cholesterol to bile acids constitutes a major pathway by which cholesterol is eliminated from the body. Targeting this step in cholesterol metabolism, one group has studied the effects of increasing cholesterol 7 -hydroxylase expression since this is the rate-limiting enzyme in this process. To this purpose, wild-type hamsters were infected with adenovirus expressing cholesterol 7 -hydroxylase [Spady et al., 1995] . In addition to enhanced conversion of cholesterol into bile acids and increased de novo cholesterol synthesis, these investigators noted a decrease in LDL secretion into the circulation but unaltered hepatic uptake of cholesterol from the circulation. This led to the hypothesis that hepatic up-regulation of cholesterol 7 -hydroxylase might also lead to decreased plasma LDL-C levels even in the absence of hepatic LDL receptors (see Fig.   1G ). Indeed, adenoviral-mediated hepatic over-expression of cholesterol 7 -hydroxylase in LDL receptor deficient mice induced a dramatic decrease of plasma LDL-C levels, entirely due to decreased LDL secretion from the liver [Spady et al., 1998 ].
CONCLUDING REMARKS ON REDUCING LOW-DENSITY LIPOPROTEINS
The current HD-Ad, AAV and lentiviral vectors allow for persistent expression of LDL or VLDL receptors without evoking major immune responses in animal models for FH. Despite these promising data, no investigators are to our knowledge preparing for clinical application to treat FH in the near future. One of the reasons for this might be the challenge of pre-existing immunity against the viral vectors in the general population. For a recent example we wish to refer to a clinical trial that was described by Manno et al., [Manno et al., 2006] . The recent development of effective gene therapeutic means to degrade specific mRNA's offers new opportunities to treat FH by degrading apoB. Especially the non-viral antisense strategy described by Kastelein et al., is promising, despite the necessity of recurrent treatment.
HIGH-DENSITY LIPOPROTEINS
HDL-C levels are inversely related to the risk of cardiovascular disease. How this lipoprotein exerts its beneficial effect is not entirely clear to date. In addition to its role in reverse cholesterol transport (RCT; often suggested to be key to anti-atherogenic action of HDL), HDL has recently been described to favorably affect endothelial function, attenuate inflammation, inhibit platelet aggregation and decrease apoptosis. The current quest to develop HDL-C increasing drugs is hampered by the notion that many of its key players need agonists to increase HDL-C levels. Here, gene therapy may offer a solution, however, as of yet no human studies have been carried out. In this respect, proof of principle may be obtained in subjects suffering from monogenetic disorders of HDL metabolism.
GENETIC CAUSES OF DECREASED HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL
Mutations in three key proteins underlie deficits in HDL synthesis and maturation and thus its functioning to protect against atherosclerosis. Apolipoprotein AI (apoAI) is the principal protein component of HDL and besides being critically involved in RCT, has numerous other beneficial effects. Complete apoAI deficiency is characterized by a near complete absence of HDL and increased risk of premature coronary artery disease. Secondly, ATP binding cassette transporter A1 (ABCA1) deficient individuals who suffer from Tangier Disease, lack the capacity to lipidate nascent or essentially lipid-free apoAI, thereby hampering HDL formation. Tangier disease patients are characterized by orange tonsils, cloudy corneas and intermittent peripheral neuropathy. With nearly absent HDL, these patients are at increased risk for atherosclerosis. Thirdly, lecithin-cholesterol acyltransferase (LCAT) deficient patients lack the capacity to esterify free cholesterol (delivered by ABCA1 action) on the surface of the HDL. This lack of cholesteryl ester synthesis in the circulation blocks maturation of nascent HDL into larger spherical HDL. Complete or partial LCAT deficiency (the latter is also known as Fish-eye Disease) is characterized by severe HDL deficiency, elevated TG levels and increased risk of atherosclerosis. Gene therapeutic efforts for these three monogenetic disorders have all focused on introducing sufficient expression of wild-type copies of the respective genes.
APOLIPOPROTEIN AI OVEREXPRESSION
ApoAI gene therapy initially focussed on the question whether this strategy would result in proper secretion and incorporation of apoAI into lipoprotein particles. Using adenoviral constructs it was shown that this was indeed the case [Kopfler et al., 1994] but the level of apoAI expression and distribution over the different lipoproteins appeared to be dependent of the mouse model of choice [Tsukamoto et al., 1997] suggesting that the efficacy of apoAI gene therapy might be dependent of the type of dyslipidemia of the recipient mouse. Subsequent development of a gene therapeutic approach for apoAI delivery focused on enhancing both expression as well as persistence of expression [De Geest et al., 2000b; De Geest et al., 2001; Van Linthout et al., 2002a] . Using various constructs these investigators evaluated the effects of 1) liver-specific promoters vs. the ubiquitously active CMV promoter, 2) genomic DNA (including introns) vs. complementary DNA encoding for apoAI, and 3) inclusion of enhancers (changing copy number and upstream/downstream position). It was shown that liverspecific promoters induced prolonged expression compared to the CMV promoter largely due to less transgene expression in antigen-presenting cells, reduced hepatotoxicity and lack of promoter-silencing [De Geest et al., 2003] . In addition, the introduction of introns in genomic DNA constructs enhanced transgene expression compared to the use of apoAI cDNA. Finally, inclusion of up to four copies of the apoEenhancer increased levels of expression significantly, with the notion that enhancers in a 5'-position increased hepatotoxicity and consequently reduced duration of expression. Eventually an adenoviral vector was constructed with the liver-specific human 1-antitrypsin promoter, genomic DNA encoding apoAI and 4 copies of the apoE enhancer in the 3'-position. This vector was shown to increase plasma levels of human apoAI to a maximum of 500 mg/dl, i.e. 3-4 times higher than human physiological levels (C57/Bl6 mice; 10-12 days after gene transfer). The expression was lost after four months indicating that promoter silencing, hepatotoxicity and immune responses were overcome in part. Loss of transgene expression at this point was ascribed to residual low-level hepatotoxicity of the viral proteins present in the adenoviral vector. Eliminating the majority of these viral proteins using a helperindependent E1/E3/E4-deleted adenovirus avoided such hepatotoxicity and resulted in persistent expression beyond 120 days. However, this came with a reduction of peak apoAI expression levels (200 mg/dl; still well above physiological levels) [Van Linthout et al., 2002b] .
More recently, other viral vectors have been employed to drive long-term apoAI expression; Hd-Ad vectors, lacking all viral proteins were shown to boost apoAI levels up to 200 mg/dl for at least 24 weeks with minimal hepatotoxicity [Belalcazar et al., 2003; Pastore et al., 2004 ]. This expression level of human apoAI on top of endogenous murine apoAI resulted in a significant increase in HDL-C level and a significant reduction of the atherosclerotic burden between 30 and 50% in both LDL receptor deficient [Belalcazar et al., 2003 ] as well as apoE deficient mice [Pastore et al., 2004] . Most recently, Oka et al. , demonstrated in apoAI deficient mice proof of principle that this approach of liverdirected Hd-Ad gene delivery is effective for long-term phenotypic correction of monogenic hypoalphalipoproteinemia .
In 2005, Sharifi et al., used AAV to mediate apoAI gene transfer in apoAI deficient mice [Sharifi et al., 2005] . An intriguing feature of this study was the use of a naturally occurring apoAI variant, i.e. apoAI-Milano instead of wildtype apoAI as the transgene. In apoAI-Milano an Arg residue is substituted for a Cys residue at position 173. In individuals carrying this mutation, apoAI-Milano is reported to be catabolized at an increased rate thereby increasing the hepatic uptake of tissue lipids conferring greater resistance against atherosclerosis [Chiesa et al., 2003 ]. Comparing AAV serotypes 1, 2 and 5 Sharifi et al [Sharifi et al., 2005] showed that AAV1 yielded highest expression both after intravenous (IV) as well as after intramuscular (IM) administration. Both administration routes showed highest apoAI expression levels at 24 weeks when the animals were sacrificed. This is remarkable when considering the use of a CMV promoter that is known to suffer from silencing. With IV injections performing best with expression up to 25 mg/dl apoAI, this is still well below apoAI levels of wild-type mice typically ranging from 60 to 100 mg/dl. This result may be explained by an enhanced catabolic rate of apoAI-Milano compared to wild-type apoAI but more likely reflects the use of a suboptimal AAV serotype. Evidence for this idea comes from studies by Kitajima et al. , who compared AAV2 with novel AAV serotypes 7 and 8 [Kitajima et al., 2005] . Whereas AAV2 encoding human apoAI and driven by a liver-specific promoter resulted in a peak expression of only 6 mg/dl after IV injection, the use of AAV7 or AAV8 increased expression up to 143 and 69 mg/dl, respectively with both serotypes also causing significant increases in HDL-C levels in C57/Bl6 wild-type mice. Furthermore, expression was persistent for up to one year.
Besides investigating the extent and duration of expression to eventually realize clinical use of apoAI gene therapy, somatic gene transfer of apoAI has also been used to better understand the role of apoAI in lipid metabolism and beyond. This includes e.g. studies into the effect of apoAI expression on neo-intima formation after endothelial denudation [De Geest et al., 1997] , vasoactive properties of HDL [Frolkis et al., 1998 ], HDL-associated proteins such as platelet-activating factor acetylhydrolase and paraoxonase 1 [De Geest et al., 2000a] , HDL assembly [Reardon et al., 2001] , cholesterol efflux from macrophages to feces [Zhang et al., 2003] and atherogenesis [Tangirala et al., 1999; Benoit et al., 1999; Belalcazar et al., 2003; Pastore et al., 2004] .
LCAT OVER-EXPRESSION
Few efforts have been made to develop a gene therapeutic strategy for treating LCAT deficiency, a disorder which can cause early death due to renal failure [Pritchard et al., 1999] . In a first study Seguret-Mace et al., used first generation adenoviral constructs for LCAT gene delivery in human apoAI transgenic mice [Seguret-Mace et al., 1996] . These investigators showed a strong increase in plasma LCAT activity and a significant increase in HDL-C with a concomitant rise in human apoA-I. Furthermore, HDL particles increased in size suggesting efficient maturation. Using adenovirus as a vector in mice lacking leptin as well as the LDL receptor, Mertens et al., subsequently showed that increased levels of human LCAT reduced the atherosclerotic burden [Mertens et al., 2003] . Intriguingly, the increase of LCAT activity in the latter experiment did not result in changes of HDL-C levels or cholesterol ester to free cholesterol ratio in plasma. Instead, the observed protection from atherosclerosis was ascribed to the prevention of LDL oxidation caused by the increased LCAT activity.
Finally, Fan et al., tested a strategy in which LCAT and its principal activator apoAI were simultaneously expressed [Fan et al., 1998; Fan et al., 1999] . Using either AAV or retroviral vectors they showed that both transgenes could be expressed and secreted from a single vector in hepatocytes and myoblasts in vitro. Although a very interesting concept, functional efficacy and evaluation in vivo have not been described.
ABCAI OVER-EXPRESSION
Wellington et al., are the only investigators who have investigated the use of gene therapy to achieve overexpression of ABCA1 [Wellington et al., 2003] . To evaluate whether hepatic overexpression could affect plasma HDL-C levels, C57/Bl6 wild-type mice were treated with an adenoviral vector in which the expression of human ABCA1 cDNA was driven by the CMV promoter. HDL-C proved to increase dose-dependently when using viral dosages up to 5x10 8 pfu. Higher dosages, however, did not further increase HDL-C but did unexpectedly dose-dependently increase total cholesterol, triglycerides, phospholipids and apoB levels in plasma. These data suggest that markedly increased expression of ABCA1 alters whole body lipid homeostasis and the authors suggested that therapeutic application can only be pursued if transgenic ABCA1 expression can be placed under physiological regulation.
CONCLUDING REMARKS ON INCREASING HIGH-DENSITY LIPOPROTEINS
Despite many efforts to achieve therapeutic correction of low HDL-C levels, clinical trials are not planned in the near future. There may be a future for apoAI gene therapy since this protein has multiple favorable properties which may drive more investigators to optimize gene delivery and expression of this protein. However, it is a challenging target since one needs very high expression levels in humans to achieve therapeutic impact. For LCAT, there exists little evidence that overexpression is indeed anti-atherogenic and as for apoAI deficiency and Tangier disease, it will be difficult to recruit sufficient numbers of patients for initial trials. When gene therapy is shown to be safe and efficacious, the use of apoAI, LCAT or ABCA1 as transgenes in patients at very high risk of cardiovascular disease may be possible.
TRIGLYCERIDES Genetic Causes of Elevated Triglyceride Levels
Hypertriglyceridemia can result from overproduction of triglyceride-rich lipoproteins or from attenuated hydrolysis and subsequent clearance of these very lipoproteins. This lipid disorder is often the result from a detrimental interaction between genetic and environmental/demographic factors. Overproduction of TG-rich lipoproteins in various genetically transmitted dyslipidemias such as FCH has in general an unknown etiology. However, impaired TG hydrolysis is in some cases caused by well-defined defects in key enzymes involved in this process. Homozygosity or compound heterozygosity for mutations in e.g. lipoprotein lipase (LPL), the critical enzyme of TG hydrolysis in the circulation, leads to massive elevation of plasma TG levels, also known as chylomicronemia (accumulation of TG-containing chylomicrons in the circulation). Mutations in the primary cofactor of LPL, i.e. apolipoprotein CII (apoCII) cause a nearly identical phenotype. More recently, defects in apoAV have also been shown to cause hypertriglyceridemia but often in combination with increased total cholesterol levels.
Regarding gene therapeutic efforts to treat hypertriglyceridemia, LPL deficiency has been the main focus. Several factors make this rare genetic disorder a interesting target. First of all, LPL deficiency is a potentially life-threatening disorder that in general is associated with a low quality of life. Current treatment strategies are often insufficient to prevent hospitalization due to acute haemorrhagic pancreatitis. Importantly, the majority of patients suffer from LPL mutations that result in loss of catalytic activity but the mutated protein is still produced and secreted into the circulation. Hence, transgenic LPL is less likely to induce an immune response. Finally, this disorder can be phenotypically corrected by only partially restoring LPL activity levels.
Increasing Lipoprotein Lipase
In 1995 the first in vitro studies demonstrated that inducing LPL expression resulted in proper secretion of catalytically active LPL by a variety of cell species [Lewis et al., 1995; Liu et al., 1997] . This fits with the natural expression of LPL in many tissues in early development. In adulthood, however, LPL is expressed in skeletal muscle, cardiac muscle, adipose tissue and macrophages. Using adenoviral vectors, Excoffon et al., showed that ectopic expression of LPL in the liver of heterozygous LPL deficient mice resulted in the secretion of catalytically active LPL which caused a decrease in predominantly VLDL-TG . Importantly, the transgenic LPL improved postprandrial TG clearance when the treated mice were challenged with an oral fat load. However, the hepatotoxic nature of this early adenoviral vector resulted in negligible LPL mRNA levels in the liver at 42 days after gene transfer. Further studies with adenovirus demonstrated that LPL overexpression could also alleviate hyperlipidemias of a different nature. In apoE deficient mice and LDL receptor deficient mice [Zsigmond et al., 1997] LPL gene therapy was shown to result in marked reductions plasma TG levels (63% and 40%, respectively) and total plasma cholesterol levels (48% and 43%, respectively). Using the same approach, Liu et al., even showed that TG hydrolysis could be enhanced in wild-type mice [Liu et al., 1998 ]. An important step toward human application was a proof-of-principle study in a large, natural-occurring animal model; the LPL-deficient cat [Liu et al., 2000] . Using the same adenoviral vector in this model, it was shown that ectopic LPL expression caused a striking 90% reduction of plasma TG levels but only for up to 2 weeks. An antibody response against both viral proteins as well as the human LPL protein could explain this transient expression. The latter could be related to the fact that these animals are homozygous for a null-mutation for LPL in which case the introduced human LPL protein acted as a neo-antigen. Despite this draw back, this study demonstrated that phenotypic correction of hypertriglyceridemia due to complete LPL deficiency could be efficiently corrected using somatic gene transfer. On the other hand, vectors that could mediate long-term expression were needed. A murine model of complete LPL deficiency was subsequently generated to further develop LPL gene therapy [Strauss et al., 2001; Ross et al., 2005] . In pursuit of long-lasting transgene expression, these investigators switched to IM administration of AAV serotype 1 to express LPL S447X [Ross et al., 2004] . Compared to the wild-type protein, LPL S447X has been shown to be associated with decreased plasma TG, increased HDL-C, and reduced risk of coronary artery disease (for review see ) Expression of LPL S447X was thus reasoned to be superior to expression of LPL WT , as a means to reduce TG levels . Using this approach, partial restoration of LPL activity levels (33%) resulted in a nearcomplete normalization of plasma TG, TC, HDL-C and free fatty acid levels for over one year. Moreover, the TG clearance after an intravenous fat load, impaired in LPL deficient mice, was greatly improved upon treatment with LPL S447X . This very strategy also proved effective in the LPL-deficient cat but again this effect was only transient (2 weeks): similar to using Ad-LPL, development of neutralizing antibodies was observed . Combined with safety and biodistribution studies , these proof of principle studies allowed for the initiation of a first clinical trial. This trial started in October 2005 and focused on safety and efficacy of the IM application of AAV1-LPL S447X in LPL deficient patients. All these patients have low to normal levels of catalytically inactive LPL in the circulation. The presence of this mutated protein is anticipated to reduce chances on the development of an immune response of the host against the transgene product . Currently all 8 participants have been included and results of this trial are anticipated in the near future.
APOAV OVER-EXPRESSION
Since the discovery of apoAV in 2001 [Pennacchio et al., 2001; van der Vliet et al., 2001] , 3 premature truncation mutations have been described that in combination with secondary causes, e.g. pregnancy, age and obesity, lead to massive elevation of plasma TG levels in man [Oliva et al., 2004; Marcais et al., 2005; Oliva et al., 2006] . Although not directly aimed at developing a therapy, several investigators have shown that adenoviral vectors can be successfully used to induce overexpression of apoAV which is naturally expressed in the liver. Treating apoAV-deficient mice which have severely increased plasma TG levels with an adenovirus expressing human apoAV resulted in a marked 70% decrease in TG levels and a cholesterol-lowering in all lipoprotein classes but especially in HDL [van der Vliet et al., 2002] . Using the same adenoviral approach in wild-type C57/Bl6 mice, the TG-lowering effect of apoAV overexpression was shown to be predominantly caused by stimulation of LPL-mediated TG hydrolysis and reducing the hepatic VLDL-TG production rate [Schaap et al., 2004] . Recently, Huang et al., [Huang et al., 2006] demonstrated that adenoviral-mediated expression of apoAV in apoE deficienct mice, also results in strong decreases of plasma cholesterol and triglyceride levels by 58 and 75%, respectively at day 7 after gene transfer. Remarkably, however, in these apoE deficient mice HDL-C levels remained unchanged.
CONCLUDING REMARKS ON DECREASING TRIG-LYCERIDES
The first clinical gene therapy trial to increase LPL using intramuscular application of AAV serotype 1 is currently under way. If this strategy proves safe and efficacious, it may set the stage for gene therapy to treat other monogenetic disorders of lipid metabolism as described in this review. In addition, such therapy may be applicable for other inherited diseases for which there exists no or insufficient medication to date.
FUTURE DIRECTION AND CONCLUDING RE-MARKS
With a history of 2 decades and one landmark study in humans [Grossman et al., 1995] , gene therapeutic approaches in treating dyslipidemia are still maturing. This actually holds true for the entire gene therapy field, mainly because the current viral vectors are still not ideal. Although Hd-Ad, lentiviral and AAV vectors are promising in terms of expression levels and toxicity, immune responses against the viral capsid proteins hamper their clinical application. Indeed, exposure to these viral vectors invariably leads to the mount of an adaptive immune response. This not only prevents repeated administration, but also poses an initial problem since a large part of the general population has a pre-existing immune response due to earlier encounters with the natural variants of these viral vectors. Recent developments are therefore aimed at circumventing pre-existing immune responses for example by using vectors with coating proteins that are not recognized by the host such as different viral serotypes from other species that are not present in humans [Parks et al., 1999; Wu et al., 2006; Nathwani et al., 2006] , hybrid vectors [Wu et al., 2006] and viral particles with masked capsid proteins [O'Riordan et al., 1999] ). Other investigators focus on antigen presenting cells (APCs) such as macrophages which can function as the initiators of adaptive immune responses. Modulation can be achieved for example by immune-suppressive regimes [Smith et al., 1996; Manning et al., 1998; Hamada et al., 2005] , temporarily eliminating these APCs for example using dichloromethylene-biphosphonate [Zhang et al., 2001] or by expressing immuno-suppressant sequences, e.g. gp19 [Wang et al., 2003a] , to prevent presentation of the viral MHC components.
Given the ongoing development of better-equipped vectors, especially with respect to avoiding immune responses, it appears that clinical application is at the horizon. For the lipid research field, gene therapy is likely to be tested in various cohorts with monogenetic lipid disorders. Only if these trials proof to be safe and efficacious, broader application for patients at very high risk of cardiovascular disease may be possible. 
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